



ASX Release
28 March 2019

Rights Issue Prospectus Completion

Pursuant to the Non-renounceable Rights Issue Prospectus dated 28 February 2019 and lodged with ASIC and ASX on same day, the following securities have been allotted today:

Shares issued to applicants:	88,508,701
Additional shares applied for and issued to applicants:	6,228,073
Shortfall allotment:	87,307,799
Total allotment of shares:	182,044,573
Total shares on issue after allotment:	546,133,718

For further information please contact:

Alison Coutts
Executive Chairman
Memphasys Limited
+61 2 8415 7300
alison.coutts@memphasys.com

David Tasker
Managing Director
Chapter One Advisors
+0433 112 936
dtasker@chapteroneadvisors.com.au

About Memphasys:

Memphasys Limited (**ASX: MEM**) specialises in biological separations for high value commercial applications. The Company's patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.